REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
David M WeinreichSumathi SivapalasingamThomas NortonShazia AliHaitao GaoRafia BhoreBret J MusserYuhwen SooDiana RofailJoseph ImChristina PerryCynthia PanRomana HosainAdnan MahmoodJohn D DavisKenneth C TurnerAndrea T HooperJennifer D HamiltonAlina BaumChristos A KyratsousYunji KimAmanda CookWendy KampmanAnita KohliYessica SachdevaXimena GraberBari KowalThomas DiCioccioNeil StahlLeah LipsichNed BraunsteinGary HermanGeorge D Yancopoulosnull nullPublished in: The New England journal of medicine (2020)
In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group. (Funded by Regeneron Pharmaceuticals and the Biomedical and Advanced Research and Development Authority of the Department of Health and Human Services; ClinicalTrials.gov number, NCT04425629.).
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- immune response
- healthcare
- coronavirus disease
- end stage renal disease
- mental health
- ejection fraction
- newly diagnosed
- primary care
- peritoneal dialysis
- prognostic factors
- type diabetes
- toll like receptor
- adipose tissue
- dengue virus
- zika virus
- dendritic cells
- patient reported outcomes
- inflammatory response
- skeletal muscle
- risk assessment
- patient reported
- open label
- glycemic control